Clinical Trial Update: Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates Abemaciclib in patients with advanced, unresectable, and/or metastatic digestive system neuroendocrine tumors; the study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neuroendocrine Neoplasm
• Foregut Neuroendocrine Tumor
• Hindgut Neuroendocrine Tumor
• Midgut Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Unresectable Digestive System Neuroendocrine Neoplasm

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: University of Washington | Conditions: Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING